Leukemia
Mutations of the transcription factor AML1/CBFA2 are uncommon in blastic transformation of chronic myeloid leukaemia TO 
THE EDITOR
The genetic basis for the transition of chronic myeloid leukaemia (CML) from chronic phase to blast crisis is poorly understood. Recently, mutations in the runt domain of CBFA2 (also known as AML1), or loss of one CBFA2 allele, have been described in a subset of patients with acute myeloid leukaemia (AML). [1] [2] [3] The objective of this study was to determine if similar mutations are also associated with disease progression in CML.
DNA was extracted using standard techniques from peripheral blood or bone marrow samples from 55 patients with BCR-ABL-positive CML in blastic phase (CML-BC). All samples had at least 50% blast cells and chronic phase DNA was available for 17 of the 55 cases. Three DNA samples from patients with AML who were known to have CBFA2 runt domain mutations were kindly provided as positive controls by Dr C Preudhomme (Laboratoire d'Hematologie, Hopital Calmette-CHU, Lille, France). Negative control DNAs from two normal individuals were also analysed.
Initially, we used PCR-SSCP analysis to look for mutations in the runt domain of CBFA2 (encoded by exons 3, 4 and 5). These exons were individually amplified from 100 ng of patient DNA by 30 cycles of PCR using an annealing temperature of 56°C. The primers employed were identical to those published elsewhere. 1 To reduce the presence of non-specific background products we found it necessary to perform a second nested amplification for exon 3 products using the internal primers E3F (5Ј-ACCTTGAAAGCGATGGGCAG-3Ј) and E3R (5Ј-CAATCGGCTTGTTGTGATGC-3Ј). One l of PCR product was labelled by reamplification for three cycles, incorporating 2 Ci ␣-32 P dCTP per reaction and reducing the concentration of unlabelled dCTP to 3 M. Labelled fragments were denatured in formamide and electrophoresed at room temperature on 6% polyacrylamide gels containing (1) 0.5 × TBE (45 mM Tris pH 7.8, 45 mM boric acid, 1 mM EDTA) plus 5% glycerol and (2) 1 × TME (30 mM Tris pH 6.8, 35 mM 2(N-morpholino-)ethanesulfonic acid, 1 mM EDTA) as described. 4 For exon 3 we found it necessary to run the gels at 4°C in order to generate clearly discernable bands. Gels were dried and exposed to Kodak X-OMAT (Sigma, St Louis, MO, USA) film at −70°C. Exons 3-5 were successfully amplified from all 55 patients with CML-BC, the three positive control and two negative control samples. Band shifts were detected in all three positive controls, but not in any patient with CML or the normal controls. Representative results are shown in Figure 1 .
To determine if there was loss of heterozygosity (LOH) at the CBFA2 locus during disease progression, we analysed two polymorphic markers in 17 patients for whom we had samples from both chronic and blastic phases. One hundred ng of matched chronic phase and blast crisis DNA were amplified for two polymorphic markers that lie within the CBFA2 locus. Marker 56-85 is located immediately downstream of CBFA2 and was amplified using conditions described previously. 1 Marker 57-71, which is located in CBFA2 intron 4, was amplified using primers 57F (5Ј-CCTTAGAGAGTTTTAGGGGAG-3Ј) and 57R (5Ј-GTGCTTCCTCGGTCCACGACTCAGG-3Ј). Amplified products were labelled as described above and electrophoresed on non-denaturing 6% acrylamide, 0.5 × TBE gels. All 17 patients were informative (ie polymorphic) for one or both markers analysed. Comparison of matched chronic phase and blast crisis samples revealed no change in band intensity, indicating no allele loss (not shown). No additional bands were observed on transformation indicating an absence of microstatellite instability, consistent with results that we have reported previously. it is likely that some genetic abnormalities involved in the pathogenesis of AML are also responsible for the transition of CML from chronic phase to blast crisis, we failed to identify any CBFA2 mutations in 55 patients with CML-BC. Combining these results with other studies, 2, 3 CBFA2 mutations have been detected in only a single CML-BC case out of 84 tested (1.2%). We conclude therefore that CBFA2 mutations do not play a significant role in the progression of CML to blast crisis.
